Vélez Juan, Lange Malin K, Zieger Peter, Yoon Ilkyu, Failing Klaus, Bauer Christian
Institute of Parasitology, Justus Liebig University Giessen, Schubertstrasse 81, 35392, Giessen, Germany.
Diamond V, Cedar Rapids, IA, 52404, USA.
Vet Parasitol. 2019 May;269:57-64. doi: 10.1016/j.vetpar.2019.04.008. Epub 2019 Apr 19.
The objective of this study was to compare the effect of non-GMO Saccharomyces cerevisiae fermentation products (SCFP) with that of a halofuginone treatment against Cryptosporidium parvum infection in pre-weaned calves on a commercial dairy farm. A total of 123 neonatal female calves, housed in individual hutches, were enrolled sequentially based on date of birth in 41 blocks of 3 animals each. Calves within each block were allocated to one of 3 treatments: remaining untreated, fed with SCFP (Diamond V SmartCare at 1 g/d in milk and NutriTek at 5 g/d in starter grain) for the first 63 days of life, or treated with halofuginone (0.1 mg/kg/d) for the first 7 days of life. Fecal samples collected on days 4-21 post-partum were examined for both Cryptosporidium oocysts and coproantigen. The presence and intensity of diarrhea were monitored by scoring daily for the first 4 weeks of life. Calves were weighed at 0, 21, 42 and 63 days of age. Almost all calves were Cryptosporidium-positive at least once during the study. Halofuginone significantly reduced the number of Cryptosporidium-positive fecal samples as compared to the two other groups. Based on the coproantigen scores, both halofuginone and SCFP feeding significantly reduced the intensity of Cryptosporidium infection as compared to the untreated group. Diarrhea was recorded in almost all calves at least once. Neither the proportion of diarrheic calves nor the intensity and duration of diarrhea differed among the 3 treatment groups significantly. The mean daily weight gain during the first 3 weeks of life was significantly lower in halofuginone treated calves than in both other groups; however, at the end of the study period the total weight gain did not significantly differ among the 3 treatment groups. In conclusion, the clinical results and weight gains of pre-weaning supplementation with the SCFP were neither better nor worse than the 7-day halofuginone treatment suggesting that the SCFP feeding may be from the clinical point of view a natural alternative measure, instead of halofuginone treatment, in bovine cryptosporidiosis.
本研究的目的是比较非转基因酿酒酵母发酵产品(SCFP)与常山酮治疗对商业化奶牛场断奶前犊牛隐孢子虫感染的效果。总共123头新生雌性犊牛,单独饲养在犊牛栏中,根据出生日期依次分为41个区组,每组3头。每个区组内的犊牛被分配到3种处理之一:不进行处理、在出生后的前63天饲喂SCFP(牛奶中添加1克/天的Diamond V SmartCare,开食料中添加5克/天的NutriTek)或在出生后的前7天用常山酮(0.1毫克/千克/天)进行治疗。在产后第4至21天采集粪便样本,检测隐孢子虫卵囊和粪便抗原。在出生后的前4周每天对腹泻的存在和严重程度进行评分,监测腹泻情况。在犊牛0、21、42和63日龄时称重。在研究期间,几乎所有犊牛至少有一次隐孢子虫检测呈阳性。与其他两组相比,常山酮显著减少了隐孢子虫阳性粪便样本的数量。根据粪便抗原评分,与未处理组相比,常山酮和SCFP饲喂均显著降低了隐孢子虫感染的严重程度。几乎所有犊牛至少有一次记录到腹泻。3个处理组之间腹泻犊牛的比例、腹泻的严重程度和持续时间均无显著差异。常山酮处理的犊牛在出生后前3周的平均日增重显著低于其他两组;然而,在研究期末,3个处理组的总增重没有显著差异。总之,断奶前补充SCFP的临床结果和体重增加情况不比7天的常山酮治疗好,也不比其差,这表明从临床角度来看,在牛隐孢子虫病中,饲喂SCFP可能是一种天然的替代措施,而非常山酮治疗。